Cymbalta Superior To SSRIs, Lilly Says; Once-Daily Dosing Not Vital To Uptake
Executive Summary
Lilly's pending SNRI Cymbalta induces remission from depression more often than selective serotonin reuptake inhibitors, Exec VP-Science & Technology Steven Paul, MD, said